CS and malaria: The results indicate that immunization with an epitope-focused VLP containing selected B and T cell eptiopes from the P. falciparum CS protein formulated in adjuvants acceptable for human use can elicit sterile immunity against blood stage malaria if sufficient anti-CS protective Abs are produced.